A
Clinical-stage drug developer with two candidates: forvisirvat (SP-624), a SIRT6 activator in Phase 2b/3 for major depressive disorder, and RABI-767 for predicted severe acute pancreatitis.
At a glance
- Founded: 2016
- HQ: Morrisville
- Sector: Biotech
- Stage: Series B
- Total raised: $94.3M
See the full company record.
Founders, funding history and recent signals. Free accounts open immediately.
Sourced company notes 3 topics
Notes on Arrivo BioVentures · last checked Oct 1, 2026
Overview
Holding company for Sirtsei Pharmaceuticals (forvisirvat, SP-624) and Panafina (RABI-767), with licensing partnerships with the Mayo Clinic and Daiichi Sankyo. Headquartered at 3000 RDU Center Drive, Suite 130, Morrisville.
Funding
Launched publicly on 2016-05-25 with $49 million in committed capital led by Jazz Pharmaceuticals, with Solas BioVentures Fund I and Rex Health Ventures participating; the 2016 Form D records $49,000,000 sold to 34 investors. Series B closed 2023-11-29: $45.25 million committed, led by Orlando Health Ventures with Solas BioVentures Emerging Healthcare Fund and Rex Health Ventures; the Form D reports $43,194,016 sold to 58 investors. The company states $100 million raised since inception; the recorded rounds sum to $94.25 million.
Team
Founded by Steve Butts, Bill Wofford, Michael Ackermann, and Jed Black, the operating team behind Aerial BioPharma (lead drug sold to Jazz, 2014), Neuronex (acquired by Acorda, 2012), and Addrenex (acquired by Shionogi, 2009). Management as of September 2026: Stephen E. Butts (CEO), Karen Adams (CFO), Joel Raskin (CMO), Kelly Abernathy (COO, promoted 2026-02-03), Greg Rigdon (SVP Scientific Affairs), John Hixon (Head of Corporate Development).
Listed roles
All Triangle rolesChecking listed roles…